Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients Patrizia Weber, MD, S. Morteza Seyed Jafari,

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients Noël Emile Célestin.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Applying for dermatology residency is difficult and expensive

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial Lauren Okon, MD, Misha Rosenbach, MD, Michael.

Lip edema Journal of the American Academy of Dermatology

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Pediatric psoriasis treated with apremilast

Appearance of lentigines in psoriasis patients treated with apremilast

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled.

Tofacitinib therapy for children with severe alopecia areata

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Numerous hyperpigmented macules of the oral mucosa

Efficacy and safety of oxymetazoline cream 1

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp,

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial Diane Thiboutot, MD, David.

Presentation transcript:

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis Robert Bissonnette, MD, David M. Pariser, MD, Norman R. Wasel, MD, FRCPC, Joana Goncalves, MD, Robert M. Day, PhD, Rongdean Chen, PhD, Michael Sebastian, MD Journal of the American Academy of Dermatology Volume 75, Issue 1, Pages 99-105 (July 2016) DOI: 10.1016/j.jaad.2016.02.1164 Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Patient disposition for the PSOR-005, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1, and ESTEEM 2 clinical studies. PPPGA, Palmoplantar Psoriasis Physician Global Assessment. Journal of the American Academy of Dermatology 2016 75, 99-105DOI: (10.1016/j.jaad.2016.02.1164) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Achievement of Palmoplantar Psoriasis Physician Global Assessment (PPPGA) score of 0 (clear) or 1 (almost clear) at week 16 in patients with a PPPGA score 3 or higher at baseline, indicating moderate or severe palmoplantar psoriasis. Missing values were handled using nonresponder imputation. n/N, number of patients with response/sufficient data for evaluation. *P = .021 by Fisher exact test versus placebo. Journal of the American Academy of Dermatology 2016 75, 99-105DOI: (10.1016/j.jaad.2016.02.1164) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Effect of apremilast 30 mg twice daily in a patient with palmoplantar psoriasis at baseline (Palmoplantar Psoriasis Physician Global Assessment [PPPGA] score = 3) (A) and week 16 (PPPGA score = 0) (B). Journal of the American Academy of Dermatology 2016 75, 99-105DOI: (10.1016/j.jaad.2016.02.1164) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Achievement of Palmoplantar Psoriasis Physician Global Assessment (PPPGA) score of 0 (clear) at week 16 in patients with a PPPGA score 1 or higher at baseline, indicating the presence of any palmoplantar psoriasis. *P < .001 by Fisher exact test versus placebo. BID, Twice a day. Journal of the American Academy of Dermatology 2016 75, 99-105DOI: (10.1016/j.jaad.2016.02.1164) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions

Fig 5 Achievement of Palmoplantar Psoriasis Physician Global Assessment (PPPGA) score of 0 (clear) or 1 (almost clear) with 1-point or more improvement at week 16 in patients with a PPPGA score 1 or higher at baseline, indicating the presence of any palmoplantar psoriasis. *P < .001 by Fisher exact test versus placebo. BID, Twice a day. Journal of the American Academy of Dermatology 2016 75, 99-105DOI: (10.1016/j.jaad.2016.02.1164) Copyright © 2016 American Academy of Dermatology, Inc. Terms and Conditions